Bahrain vs Uzbekistan: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Bahrain
99.0%
in 2025
Uzbekistan
99.0%
in 2025
Bahrain rank
1st
Uzbekistan rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Bahrain
- Uzbekistan
How they compare
Bahrain currently reports 99.0% against 99.0% in Uzbekistan, a difference of 0.0%.
The two have swapped places 7 times across 18 shared years of data; in 2008 it was Bahrain ahead.
Bahrain ranks 1st and Uzbekistan ranks 1st of 194 countries.
Bahrain has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bahrain | Uzbekistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 55.0% | 0.0% | 55.0% | Bahrain |
| 2010s | 98.3% | 29.4% | 68.9% | Bahrain |
| 2020s | 98.8% | 97.0% | 1.8% | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Bahrain or Uzbekistan?
- Bahrain, at 99.0% against 99.0% in Uzbekistan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Bahrain and Uzbekistan?
- 0.0%, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Uzbekistan?
- 18 years are reported by both, from 2008 to 2025.
- How do Bahrain and Uzbekistan rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Bahrain ranks 1st and Uzbekistan ranks 1st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.